Montelukast in Acute RSV Bronchiolitis

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

There is evidence of inflammatory mechanisms in RSV bronchiolitis with increased cysteinyl-leukotrienes (cys-LT). Recently, specific cys-LT receptor antagonists - montelukast (Singulair©) approved for use in infants as granule sachets, have become available. We evaluated the effect of Singulair© on clinical progress and on cytokine profiles in the acute phase of RSV bronchiolitis.

• Phase: N/A

Details

• Lead Sponsor: Ziv Hospital
• Collaborator: Wolfson Medical Center
• Treatments: Montelukast

Criteria

Inclusion Criteria:

• Age > 4 weeks < 2 years

• Duration of respiratory symptoms < 4 days

• Signs of bronchiolitis: prodromal rhinorrhea and cough, followed by at least two of the following signs: chest retractions, tachypnea, wheezing, or rales

• First episode of wheezing or shortness of breath

• Randomization within 12 hours of admission

• No need for steroid treatment in the ward

• Informed consent

Exclusion Criteria:

• A history of asthma symptoms or any previous hospital admissions with respiratory tract illnesses and if they had ever been treated with anti-asthma medications (prior to the current illness).

• Underlying cardiopulmonary disease such as bronchopulmonary dysplasia, congenital heart disease, immunodeficiency, or cystic fibrosis.